🇺🇸

Corporate Governance

· daily

US Corporate Board Director Changes SEC Filings — October 22, 2026

Across the 50 filings for the 'USA Board Room Changes' stream (all dated 2026-10-22 window), the dominant theme is a heavy concentration of officer and director transitions, with a notable cluster of identical Invesco fund-complex Item 5.02 filings in which Kelli Gallegos began a leave on October 19 and Lori Anello was appointed PFAO effective October 22; these are administrative and carry little standalone investment signal. The filings that do carry financial content show a clear divergence: Ategrity Specialty grew gross written premiums 14.7% and net earned premiums 35.7% with a record-low 84.7% combined ratio while net income fell 35.7% YoY on investment losses, Deckers posted a record $1.481B quarter (+3.5%) but with comparable DTC down 6.4% and a $0.28 tariff-refund EPS benefit masking underlying weakness, and Lindsay's full-year revenue fell 6% to $635.9M and operating income fell 24% despite a strong Q4. Fractyl Health's cost-reduction package (roughly 45% workforce cut, Rejuva wind-down, operating burn targeted to fall ~50% to about $8M per quarter) is the most material restructuring in the set. Governance-quality signals are generally benign, with most resignations explicitly stating no disagreement, though several C-suite succession events (Forgent CFO, Comfort Systems CFO, Plumas CFO, Kinsale CFO, FHLB New York CEO) concentrate finance and leadership change in the same window. Most filings lack insider-trading or capital-allocation data, so conviction read-throughs are limited.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 21, 2026

The 'Executive Compensation Insights' stream is a themed digest focused on annual proxy statements revealing executive pay, governance, and shareholder proposals. Of the five filings provided, the stream's focus is best served by the proxy statements that touch on governance and shareholder approval mechanics, but none of the five filings supplied contain the executive compensation tables, pay ratios, or say-on-pay outcomes that define this stream. The dominant themes are capital structure actions and governance housekeeping rather than pay: Banzai International is seeking authority to nearly triple its authorized common stock and raise up to $14M at a potential discount of up to 50%, signaling acute liquidity pressure. Jasper Therapeutics needs stockholder approval for conversion of non-voting preferred issued in a completed merger, and Rezolute is asking for a 36% increase in authorized shares alongside a non-binding say-on-pay vote. WhiteFiber and iM Global Partner Funds present routine director elections and board-composition items, with WhiteFiber's controlling parent able to approve all matters alone. No enriched period-over-period, insider-activity, or compensation-quantum data was supplied for these filings, so quantitative trend claims are limited and the digest relies on the qualitative content of each proxy.

5 high priority 5 total filings
· daily

US Executive Officer Management Changes SEC — October 21, 2026

Across the 11 filings dated October 21, 2026, the dominant theme is governance and leadership renewal rather than financial performance: six of the eleven filings are newly published and cover board additions, CEO/President successions, or executive retirements, while none of the filings disclose period-over-period revenue, margin, or guidance data. The clearest pattern is succession planning being formalized ahead of key milestones: Voyager Therapeutics' President-to-CEO handoff is tied to a Q1 2027 safety readout, OPAL Fuels' co-CEO retirement is set for March 31, 2027, and Dell's General Counsel transition runs through April 30, 2027. Board refreshment is also prominent, with Bank of America adding Jim Fitterling and Bill Thomas, Entravision adding Brian Krzanich and Gary Ferrera while two long-tenured directors exit, and FMC expanding to 10 seats under an investor agreement. MillerKnoll's permanent CEO appointment of interim leader Jeff Stutz is the most operationally significant development, given the Board's citation of improved operating income and margins under his interim tenure, though no quantitative period comparison was disclosed. Insider-activity and capital-allocation data are largely absent; the notable exception is Sky Century's $205,000 salary-to-equity conversion, a small but dilutive event. Net implication: near-term market impact is modest, with the most actionable items being post-transition execution risk and dilution or governance signals in micro-cap names.

11 high priority 11 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 21, 2026

Across the 11 filings, the dominant theme is governance and leadership churn rather than financial performance: nearly every filing is an officer or director change, and none of the enriched period-over-period, guidance, or capital allocation fields carry quantitative content for this stream. Six filings are newly published (Entravision, OPAL Fuels, Dell, FMC, Bank of America, Opendoor) and five are context (Voyager, Sky Century, MillerKnoll, Aptera, Galaxy Gaming). The most consequential developments are CEO/President succession planning at Voyager (Swartz as President, expected CEO after Q1 2027 safety data), the MillerKnoll permanent CEO appointment of a long-tenured CFO-turned-COO, and the orderly CEO retirement at OPAL Fuels with a sole-CEO structure from March 31, 2027. Board refreshes at Entravision (Audit Committee chair departure) and Bank of America (two high-profile outside directors) signal governance renewal, while the FMC board seat tied to Tessenderlo's 30.3M-share stake formalizes a strategic investor relationship. The Sky Century conversion of $205,000 accrued salary into 4.1M shares (about 4.5% dilution) is the only clear capital-structure event. Overall, the stream points to a cluster of planned, largely orderly transitions, with the forward-dated catalysts concentrated in late 2026 and H1 2027.

11 high priority 11 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 20, 2026

This Executive Compensation Insights digest covers 16 US SEC DEF 14A/DEFM14A proxy filings, 13 newly published and 3 included for context. The stream is scoped to annual proxy statements revealing executive pay, governance, and shareholder proposals, so filings are assessed on their governance content: director elections, say-on-pay votes, auditor ratifications, equity plan share increases, reverse splits, dilution authorizations, and SPAC extension votes. The dominant governance theme is a cluster of micro-cap and SPAC issuers seeking shareholder approval for deadline extensions, reverse splits, or authorized-share increases, which signals financing stress and listing-compliance pressure rather than executive pay strength. Among operating companies with quantified results, Fabrinet reported fiscal 2026 revenue up 35.7% YoY and net income up 42.3% YoY alongside a 10 bp GAAP gross margin decline, while Nutanix reported revenue up 12% and ARR up 16% YoY with record free cash flow of $841 million but flagged hardware cost and lead-time headwinds. Most filings contain little or no period-over-period financial data, so the quantitative read-through is thin for much of the batch. Governance-side, the notable items are the Nutanix equity plan reserve increase, the DSS and Benitec shareholder votes, and the Greenbacker merger consideration of $375 million, which is the largest transaction value in the set.

16 high priority 16 total filings
· daily

US Executive Officer Management Changes SEC — October 20, 2026

This stream covers 23 Officer Change and Director Change 8-Ks dated October 20, 2026, and the dominant theme is leadership renewal rather than distress: most filings are board additions or orderly succession (retirements, planned transitions, new CFOs or COOs) with no quantified financial results. The clearest quantitative signal comes from Neptune Insurance Holdings, which reported record Q3 2026 results (revenue +34.3% YoY to $59.6M, net income +49.9%, written premium +31% to $132.7M) but where twelve-month net income was flat and net income margin fell 7.6pp to 22.7%, with share-based compensation jumping from $0.1M to $7.0M. Clearfield's CEO retirement carries the most near-term event risk, with its fiscal Q4 and full-year results (in line with guidance) due November 10, 2026 and a CEO search launching now. Several governance-driven situations stand out: Laser Photonics' CFO appointment is paired with outside securities and reporting counsel, signaling remediation of financial accountability, while PDS Biotechnology replaced four directors and Silvia (formerly ProCap) announced a >$10M cost-cutting program alongside executive additions. Board refreshes across pharma and biotech (Vertex, Insmed, Inhibikase, PDS) and financial services (Northern Trust, Whirlpool, Apollo) point to a sector pattern of adding commercial, regulatory, and capital-markets expertise ahead of late-stage development or growth initiatives. Overall the stream is largely neutral-to-positive, with the notable exceptions being the governance and cost-reset situations at Laser Photonics, PDS, and Silvia.

23 high priority 23 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 20, 2026

Across the 23 filings in the USA Board Room Changes stream, the dominant theme is leadership and board refresh rather than financial performance: roughly two-thirds are Officer Change, Director Change or Board Change events, with new independent directors added at Vertex, Insmed, Northern Trust, Whirlpool, Entravision, Suja Life, Apollo, StubHub, Huntington Ingalls and PDS Biotechnology, and senior executive transitions at Fox, Clearfield, TJX, Southwest Gas, Live Oak, Newell and Laser Photonics. Most filings contain no quantitative results, so period-over-period comparisons are available for only one company in depth: Neptune Insurance Holdings reported record Q3 2026 revenue up 34.3% YoY to $59.6M and net income up 49.9%, but net income margin fell 7.6pp over twelve months to 22.7% and Adjusted EBITDA margin improved only 1.5pp, with share-based compensation jumping from $0.1M to $7.0M. The most decision-relevant governance signals are the Laser Photonics CFO appointment alongside outside securities counsel and reporting consultants (a remediation-style pattern), the PDS Biotechnology reconstitution in which four directors resigned, the Clearfield CEO retirement with a search underway and a November 10 earnings date, and the Trade Desk option repricing that drew 232 million votes against. Market implication: board and officer churn is elevated and concentrated in small caps and biotech, while large-cap changes are mostly orderly succession and independence-enhancing additions.

23 high priority 23 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 19, 2026

This Executive Compensation Insights digest covers 18 DEF 14A and DEFM14A filings dated around October 19, 2026, but the stream is themed on executive pay, governance, and shareholder proposals, and most filings in this batch are dominated by transaction, financing, or extension votes rather than compensation disclosure. The most material development is Synaptics' all-cash $123.00 per share merger with onsemi (22% premium, 23.5x NTM non-GAAP P/E), where the board itself concedes that a competing stock-based Party A proposal could carry higher implied value. Dilution and capital-structure votes are the dominant theme: Summit Therapeutics seeks to double authorized common stock to fund a $2.0B AstraZeneca preferred placement, Future FinTech seeks a roughly 96-fold authorized share increase, and FTC Solar and Crexendo seek equity issuance and plan-capacity approvals. Several SPAC and micro-cap filers (Aimei Health, Kochav Defense) are seeking extensions that carry redemption and dilution risk to public holders, while Tesla's proxy highlights governance friction after a failed supermajority-elimination vote with 39.4% support. Period-over-period figures are largely absent from this batch, so the quantitative read is limited to disclosed capital structure, valuation, and fee data rather than YoY performance trends.

18 high priority 18 total filings
· daily

US Executive Officer Management Changes SEC — October 19, 2026

Across the 36 filings, the dominant theme is executive and director turnover concentrated in finance leadership: at least eight CFO or principal financial officer transitions (JELD-WEN, Standex, Mattel, Lear, Matrix Service, CRISPR, Torrid, CytoDyn/Home Bancorp-style interim arrangements, Medtronic-adjacent governance) reflect a broad rotation of finance talent, with several interim arrangements signalling incomplete searches. Board additions skew toward experienced operators and capital-markets executives (Tammy Fischer at Acadia, Kyle Crowley at ProPetro, Lynn Martin at Williams-Sonoma, John Frederick at Tempest, Scott Morris at Once Upon a Farm), which the filings frame as supporting capital discipline and growth. Quantitative period-over-period data is largely absent from this stream: most 8-Ks are governance announcements without financial results, so portfolio-level growth and margin trends can be measured only for the few filings that report results (Chord Energy, Home Bancorp, Venu, JELD-WEN guidance). Where results exist the picture is mixed: Chord Energy beat volume guidance and repurchased $205MM of stock, while Home Bancorp's net income fell about 13% QoQ, NIM compressed 5 bps to 4.19%, and nonperforming assets rose 37%. Several negative governance signals stand out, notably Polomar's board shrinking to three directors with committee vacancies, Professional Diversity Network and Omnitek director resignations, and BNB Standard/CEA Industries operating with interim leadership and a material weakness. The most market-relevant developments are the Expand Energy CEO appointment (Daniel Brown, effective October 26), the CRISPR CFO promotion with a pending Prasad exit, and the Medtronic/MiniMed separation completion.

36 high priority 36 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 19, 2026

Across the 36 filings in the USA Board Room Changes stream (all dated 2026-10-19 window), the dominant theme is a heavy wave of CFO and finance-leadership turnover: at least eight companies (JELD-WEN, Standex, CRISPR, Torrid, Matrix Service, Mattel, CarMax, Lear, CytoDyn, NRC Health) announced CFO or principal financial officer changes, several involving interim arrangements or overlapping transitions. Board additions dominate the rest, with a notable cluster of ex-CFOs and finance executives joining boards (Skillsoft, Exelon, Freshpet, Deloitte, ICE/NYSE). Most leadership changes are described as orderly, with no disagreement cited, though several resignations (Polomar, Professional Diversity Network, Omnitek) leave committee or board-size gaps. The filings provided largely lack quantitative period-over-period data, so trend analysis is limited; where figures exist, Home Bancorp shows deteriorating credit quality (nonperforming assets up 37% QoQ) and Chord Energy shows volume beats with $205MM of buybacks, while Medtronic completed the MiniMed separation. Market implication: finance-function transitions at mid-cap industrials and consumer names warrant monitoring for reporting continuity during year-end close.

36 high priority 36 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 16, 2026

This stream covers 11 US SEC DEF 14A and DEFM14A filings dated October 16, 2026, centered on executive pay, governance, and shareholder proposals. The filings are dominated by governance-procedural items: director elections, say-on-pay advisory votes, auditor ratifications, and reverse stock split authorizations recur across most of the set. The most material development is Victory Capital's $7.03 billion acquisition of First Eagle, which carries purchase-price adjustment risk tied to client consents and a fallback mechanism if the share issuance proposal fails. Eagle Financial's merger with JMSB is also high-materiality, with pro forma net income of $25.7 million for the six months ended June 30, 2026 versus $13.1 million standalone for JMSB, though integration charges remain unquantified. Governance concentration is a recurring pattern: Cheetah Net and Iveda both combine the CEO and Chairman roles without a lead independent director. Several filings lack quantitative period-over-period data, so trend-based conclusions are limited, and the executive compensation disclosures that anchor this stream's focus are largely absent from the excerpts provided.

11 high priority 11 total filings
· daily

US Executive Officer Management Changes SEC — October 16, 2026

The 34 filings in this Officer and Director Change stream are dominated by executive turnover rather than quantified performance: most 8-Ks carry no financial metrics, so period-over-period comparisons are largely unavailable. The clearest market-moving item is Fox Factory's preliminary Q3 FY2026 miss and FY2026 guidance cut (net sales guidance lowered to $1.35B-$1.38B from $1.42B-$1.47B; adjusted EBITDA to $140M-$150M from $176M-$196M) coinciding with the CEO's exit and an interim CEO appointment. Several CFO transitions cluster across small and micro-cap issuers (CalciMedica, WidePoint, GBank Financial, Feel The World, Emergent BioSolutions, Union Pacific), with interim or unnamed successors in multiple cases, which raises financial-reporting continuity risk. Governance activity is heavy at small caps (Quantum Cyber, Change Agents, Odyssey Marine, Waterstone, TScan) where independent director additions and resignations reshape committee composition. Corporate-action items of note include MiniMed's completed separation from Medtronic (exchange 5.4x subscribed), Odyssey Marine's 1-for-25 reverse split ahead of a merger vote, and Silver Bow Mining's dilutive CEO performance warrant package.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 16, 2026

Across the 34 filings in this Board Room Changes stream, the dominant theme is executive and board turnover rather than financial performance: most filings are officer or director departures, appointments, or compensation disclosures with no quantitative results attached. The most material development is Fox Factory's CEO exit alongside a sharp FY2026 guidance cut (net sales to $1.35B-$1.38B from $1.42B-$1.47B; adjusted EBITDA to $140M-$150M from $176M-$196M), which pairs leadership change with deteriorating fundamentals. Capital-markets and governance-driven events are also prominent: MiniMed completed its Medtronic separation (55.0M Medtronic shares exchanged for 252.8M MiniMed shares, 5.4x subscribed), Odyssey Marine announced a 1-for-25 reverse split tied to a merger, and Silver Bow Mining proposed large new CEO performance warrant grants. Several CFO transitions cluster in the period (CalciMedica, GBank, WidePoint, Union Pacific's Hamann retirement, Emergent's Lindahl retirement, Feel The World, Farmhouse), a pattern that warrants monitoring for reporting-quality or governance signals. Quantitative period-over-period data is largely absent from these filings, so comparative conclusions are limited to the handful that disclose figures.

34 high priority 34 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 15, 2026

This digest covers seven DEF 14A filings dated October 15, 2026, but the stream is framed around executive compensation, governance and shareholder proposals, and the filings themselves are dominated by meeting logistics, SPAC extension mechanics and financing terms rather than pay disclosures. No period-over-period financial comparisons, insider transactions, or quantified guidance are actually present in the filing summaries provided, so trend analysis is limited to governance and voting dynamics. The most material developments are the SPAC extension risk at ClimateRock (sponsor control of ~94% of votes, redemption-driven cash shortfall risk), the Cactus Acquisition Corp. 1 extension vote ahead of a November 2, 2026 termination date, and Boxlight's Series D preferred financing with a 20% default dividend, stated-value step-up and an unfulfilled special-meeting obligation. Several shareholder votes are close or uncertain, notably Korsana's redomestication, which previously won a majority of votes cast but failed the statutory two-thirds thresholds. Across the set, the common thread is that shareholder approval thresholds and contingent conditions, not operating performance, will determine outcomes in the near term.

7 high priority 7 total filings
· daily

US Executive Officer Management Changes SEC — October 15, 2026

The 35 filings in this stream are dominated by executive and director changes rather than financial results: most disclosures are routine board appointments, planned retirements, or CFO transitions, and very few carry quantitative period-over-period data. Across the set, CFO turnover is the most frequent theme (Verra Mobility, Sinda, Super Micro, Hyster-Yale, Actinium, Orion, Carpenter-adjacent legal transitions), with several companies replacing finance leadership within weeks of a departure, which raises execution and reporting-continuity questions. The most material developments are Bansal & Co's resignation and withdrawal of audit reports for FY2019–2025 at Ameritek Ventures, the unresolved closing condition on Hain Celestial's International divestiture, and Verra Mobility's decision to skip its Q3 earnings call amid a CFO and CEO transition. Insider-conviction signals are limited, but retention packages (MongoDB, BJ's Wholesale, Orion) and a large Super Micro CFO package suggest boards are paying up to stabilize leadership. Portfolio-level, the data show a pattern of planned succession (Hamilton Lane, ManpowerGroup, Caterpillar, Arrow, LeMaitre) that is generally low-risk, while unplanned or unexplained departures (Sinda, Super Micro, Verra) warrant closer monitoring. Because the enriched period-comparison and forward-looking fields are largely empty for these governance filings, most signals below are qualitative and should be weighted accordingly.

35 high priority 35 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 15, 2026

The 35 filings in this board-room stream are overwhelmingly governance-and-leadership disclosures rather than financial events: most carry no reported financial results, period-over-period comparisons, or forward guidance, so the enriched quantitative fields are largely empty for this batch. The dominant themes are CFO turnover (Verra Mobility, Sinda, Super Micro, Hyster-Yale, Actinium, Pineapple/Pentiv, Synaptics), director departures tied to retirements or other commitments (Blackstone/Medline Baratta, Compass Minerals, Olema, Biomerica), and planned succession at senior levels (ManpowerGroup, Hamilton Lane, Carpenter, Arrow, Caterpillar, LeMaitre). The single most material development is Ameritek Ventures, where the auditor resigned and withdrew audit reports for FY2019 through FY2025 after a court ruled the custodian improperly appointed, creating a severe reliability problem for the company's financial history. Hain Celestial's pending International divestiture to AURELIUS also stalled on a missed lender-amendment closing condition with no revised timeline. Several CFO transitions occur in close proximity to scheduled reporting dates, notably Verra Mobility's Q3 release on October 30 without a conference call, which warrants attention to the quality of that disclosure.

35 high priority 35 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 14, 2026

This digest covers 12 US SEC filings, all dated October 14, 2026, and centers on proxy statements (DEFM14A, DEF 14A) rather than executive pay disclosures. The stream focus is Executive Compensation Insights, and most filings present governance mechanics, shareholder votes, and merger or extension votes without compensation tables, so the enriched period-over-period, insider, and capital allocation fields are largely absent from the excerpts provided. The dominant theme is corporate restructuring and shareholder approval events: two large-cap transactions (Transocean/Valaris and Bowhead/American Family) and two SPAC deadline extensions (FACT II, Mountain Crest V) require holder votes in November 2026. Quantitative highlights include Atlassian's fiscal 2026 revenue up 26% y/y to $6.6 billion with Cloud revenue at $4.4 billion, Entera Bio's roughly $275 million private placement, and Valaris pro forma contract drilling revenue of $3,052 million for the six months to June 30, 2026. Governance themes include reverse split and dilution authority at Amesite, equity plan share increases at Entera Bio and Wave Life Sciences, and presiding-director and independence determinations at the Transcontinental/American Realty pair. Most filings are scheduled for November 10 to December 10, 2026 votes, so the near-term calendar is dense.

12 high priority 12 total filings
· daily

US Executive Officer Management Changes SEC — October 14, 2026

Across the 23 filings in the USA Executive & Director Changes stream (17 new, 6 contextual), the dominant theme is governance renewal: board refreshes with audit/finance expertise (Lisata, Compass, XTI, Jackson Financial, Enliven, Andersen Group), CEO and CFO successions (Verastem, PC Connection, Comtech, Mattel), and a cluster of C-suite departures at small and mid-cap names. The only filing with quantified period-over-period performance is State Street, which reported Q3 2026 diluted EPS of $3.69 (+33% YoY) and revenue of $4.0B (+13% YoY, -1% QoQ), but with mixed underlying detail: Other fee revenue fell 29% YoY and QoQ, FX trading services fell 14% QoQ, and CET1 declined 0.3 points YoY to 11.0%. Insider and compensation signals are noteworthy: Yext's 11M-share performance-based CEO option with 14 escalating price hurdles ($21 to $88.08) signals a long-dated conviction bet, while Alector's option repricing and Mattel's enhanced CEO change-in-control protections reflect retention-driven compensation design. The most material distress signals sit in Bubblr Inc., which is operating under a court-appointed receiver, with its CRO and a director resigning in early October. Several enriched financial fields (period comparisons, guidance, valuations) are empty for most filings, so the analytical edge here is primarily qualitative governance and timing.

23 high priority 23 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 14, 2026

Across the 23 filings for the USA Board Room Changes stream (all dated 2026-10-14 window), the dominant theme is leadership reshuffling rather than financial performance: at least 10 filings involve CEO, CFO, CMO, CTO, CRO, CCO or General Counsel changes, director appointments, or board expansions. Only one filing (State Street) carries substantive period-over-period financials, and it is mixed: diluted EPS up 33% YoY to $3.69 and revenue up 13% YoY, but Other fee revenue fell 29% YoY and QoQ, FX trading services fell 14% QoQ, and CET1 slipped 0.3 pp YoY to 11.0%. Most other filings report no quantitative performance data, so the signal in this stream comes from governance quality, succession planning and transition risk. The most material governance developments are Verastem's planned CEO succession (Bailey replacing Paterson effective January 1, 2027), Comtech's CFO and CLO transitions tied to the Gilat sale of its Satellite & Space segment, and the court-appointed receivership at Bubblr where the Receiver is exercising board powers and officers are resigning. Director appointments skew toward experienced audit, CFO and life-science operators (Farrow at Lisata, Templin at Jackson, Ball at Enliven, Hsiao at Compass), which is a constructive governance pattern. Compensation design is also a recurring theme, with Yext's 11M-share performance option, Mattel's CEO severance raised to 2.99x with a 280G gross-up, and Alector's underwater option repricing. Overall, the stream reads as a mix of planned succession and governance strengthening against a small cluster of distressed or abrupt departures.

23 high priority 23 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 13, 2026

This stream covers 20 DEF 14A proxy filings dated around October 13, 2026, and the enriched data is largely absent: nearly all filings report no period-over-period financial results, no insider transaction values, and no forward guidance. The governance content is the substance here, and it clusters into three recurring themes: Nasdaq listing and dilution remediation (Upexi, GT Biopharma, Healthcare Triangle, Health In Tech, Adagio Medical), reverse splits and authorized-share expansions, and concentrated voting control (Galectin, Health In Tech dual-class, Marathon Bancorp's 10% voting cutoff). Upexi is the single most material filing, with Nasdaq Staff having found two convertible note issuances in violation of Rule 5635(a) and up to ~42 million shares potentially issuable against a company whose listing is at stake. Several filings are routine director elections and auditor ratifications with no investment signal. Mutual-fund and closed-end fund proxies (Principal Funds, Principal ETFs, RMB Investors Trust, Japan Smaller Cap, SRH Total Return) concern fund governance rather than executive pay, and are treated as out of scope for this compensation-focused stream. Overall, the batch points to dilution pressure among micro-cap, Nasdaq-listed issuers, and should be read as a governance-risk digest rather than an executive-compensation one.

20 high priority 20 total filings